Ontology highlight
ABSTRACT: Introduction
The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized.Methods
Between January 18 and March 16, 2022, 34 of the 45 adult patients who received therapy with plitidepsin in the APLICOV-PC study were enrolled in E-APLICOV (median time from plitidepsin first dose to E-APLICOV enrollment, 16.8 months [range, 15.2-19.5 months]). All patients were functionally autonomous with regard to daily living (Barthel index: 100) and had normal physical examinations.Results
From the APLICOV-PC date of discharge to the date of the extension visit, neither Commo
SUBMITTER: Varona JF
PROVIDER: S-EPMC9992643 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature